Contrasting Views on the Role of Mesenchymal Stromal/Stem Cells in Tumour Growth: A Systematic Review of Experimental Design

Author(s):  
Ahmed Kolade Oloyo ◽  
Melvin Anyasi Ambele ◽  
Michael Sean Pepper
2020 ◽  
Vol 16 (2) ◽  
pp. 276-287 ◽  
Author(s):  
Alexia Karamini ◽  
Athina Bakopoulou ◽  
Dimitrios Andreadis ◽  
Konstantinos Gkiouras ◽  
Aristeidis Kritis

Bone ◽  
2009 ◽  
Vol 44 ◽  
pp. S146
Author(s):  
S. Gronthos ◽  
S. Isenmann ◽  
A. Arthur ◽  
A.C.W. Zannettino ◽  
S. Shi ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3886-3886
Author(s):  
Hongzhe Li ◽  
Roshanak Ghazanfari ◽  
Dimitra Zacharaki ◽  
Hooi Ching Lim ◽  
Stefan Scheding

Abstract Bone marrow stromal stem cells (BMSCs) are essential components of the hematopoietic environment. BMSCs play a key role in regulating hematopoiesis and, furthermore, as skeletal stem cells they give rise to osteoblasts, adipocytes, and chondrocytes. However, despite this important role of BMSCs in bone and bone marrow physiology, little is known about how proliferation, differentiation and hematopoietic support functions of BMSCs are regulated. We hypothesized that primary human BMSCs have a distinct transcriptional regulatory system, which control BMSC stem cell properties and biological functions. We have previously reported gene expression profiling of highly-enriched human primary BMSCs (Li et al, Stem Cell Reports, 3(6):965-74, 2014), which demonstrated a substantially higher expression of early growth response 1 (EGR1) in primary cells compared to the non-colony-forming cells and cultured stromal cells, respectively. EGR1 is a member of the immediate early response transcription factor family, which has a function in cell growth, development, and stress responses in many tissues. EGR1 has been previously reported to be important for hematopoietic stem cell (HSC) proliferation and localization (Min et al. Cell Stem Cell, 2(4):380-91, 2008), but its role in non-hematopoietic bone marrow cells has thus far not been investigated. Therefore, we aimed to study the possible role of EGR1 in stroma stem cell proliferation and hematopoietic supporting function. Our data demonstrate that the expression of EGR1 as measured by qPCR was 126 ± 9-fold higher in highly fibroblast colony-forming cells (CFU-F) enriched human primary linneg/CD45neg/CD271pos/CD140aneg bone marrow cells compared to the non-colony forming CD45neg/CD271neg cell population. Furthermore, EGR1 expression in CD271posCD140aneg cells was 3 ± 0.2 -fold higher than in the CD271posCD140apos cell population, which has only minimal CFU-F activity. EGR1 expression decreased dramatically during culture with a more than 30-fold difference between primary and passage one and six cells. Down-regulation of EGR1 expression by shRNA did not affect the multi-differentiation capacity (adipogenic, osteogenic) and surface marker expression profile of BMSCs in vitro compared to controls. However, colony-forming capacity and proliferation was considerably increased in EGR1 knockdown cells, i.e. shRNA- transduced stromal cells produced up to 1.8 ± 0.1-fold more CFU-F compared to controls, whereas CFU-F were virtually absent when assaying EGR1 overexpressing cells. Furthermore, population doubling times were decreased in EGR1 knockdown cells but significantly increased (2.4 ± 0.3-fold) in EGR1 overexpressing cells. These data indicate that EGR1 expression negatively regulates BMSC proliferation and colony-forming capacity. On the other hand, hematopoietic support function was decreased in EGR1 knockdown cells as measured by the production of transplantable CD34posCD90pos HSC in stroma co-culture experiments (4-day serum-free culture supplemented with SCF 25 ng/ml, TPO 25 ng/ml, and FLT3L 25 ng/ml, 1×104 CD34pos seeded cord blood cells). Here, the positive effect of the supporting stroma was neutralized by knockdown of EGR1. Numbers of CD34posCD90pos HSC produced in co-cultures with EGR1 knockdown stroma cells were as low as 1,053 ± 316 compared to 6,100 ± 840 in control co-cultures (scamble control). Without stroma, 840 ± 210 CD34posCD90pos cells were generated from 1×104 seeded CD34pos cells. Furthermore, expansion of CD34posCD90posCB cells was increased in co-cultures with EGR1 overexpressing cells, indicating that EGR1is a positive regulator of hematopoietic stroma support in human BMSC, and confirmatory in-vivo xenotransplantation studies are ongoing. In summary, EGR1 is highly expressed by primary BM-MSC compared with non-colony forming cells and is downregulated during culture. EGR1 expression negatively regulates BMSC proliferation and colony formation while positively regulating hematopoietic stroma support function. Our data thus indicate that EGR1 may act as an important BMSC regulator coordinating the specific functions of BMSC in their different biological contexts. Disclosures No relevant conflicts of interest to declare.


Science ◽  
2009 ◽  
Vol 324 (5935) ◽  
pp. 1666-1669 ◽  
Author(s):  
T. S. Stappenbeck ◽  
H. Miyoshi

2021 ◽  
Vol 20 (1) ◽  
pp. 12
Author(s):  
Dominic Augustine ◽  
Preeti Singh ◽  
RoopaS Rao ◽  
Shankargouda Patil ◽  
KamranHabib Awan ◽  
...  

2021 ◽  
Author(s):  
Eirini Martinou ◽  
Giulia Falgari ◽  
Angeliki Angelidi ◽  
Izhar Bagwan

Abstract Background: Colorectal cancer (CRC) is worldwide the third leading cause of cancer-related death, and despite therapeutic advances, survival remains low. Emerging evidence shows that Homeobox (HOX) genes are important in carcinogenesis, and their dysregulation has been linked with metastatic potential and poor prognosis. This systematic review aims to present the current evidence on the role of HOX genes as biomarkers in CRC and the impact of their modulation in tumour growth and progression. Methods: MEDLINE, EMBASE, Web of Science and Cochrane databases were searched by following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Eligible studies investigated two research questions: a) the clinicopathological and prognostic significance of HOX gene dysregulation in patients with CRC and b) the functional role of HOX genes in CRC progression. This study was registered in the international prospective register of systematic reviews (PROSPERO), CRD42020190953. Results: Twenty-five studies enrolling 3003 patients with stage I-IV CRC, showed that 26 out of 39 HOX genes were dysregulated in cancerous versus normal colon. Aberrant expression of HOX proteins was significantly related to tumour depth, nodal invasion, distant metastases, advanced stage and poor prognosis. Twenty-two preclinical studies showed that HOX proteins are crucially related to tumour growth and metastatic potential by affecting cell proliferation and altering the expression of epithelial-mesenchymal transition modulators. Conclusions: In conclusion, our findings suggest that HOX proteins play vital roles in CRC progression and significantly affect survival. Further research, though, is required to elucidate their potential role as biomarkers in CRC.


2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Ryan A. Denu ◽  
Peiman Hematti

Mesenchymal stromal/stem cells (MSCs) are multipotent stem cells present in most fetal and adult tissues.Ex vivoculture-expanded MSCs are being investigated for tissue repair and immune modulation, but their full clinical potential is far from realization. Here we review the role of oxidative stress in MSC biology, as their longevity and functions are affected by oxidative stress. In general, increased reactive oxygen species (ROS) inhibit MSC proliferation, increase senescence, enhance adipogenic but reduce osteogenic differentiation, and inhibit MSC immunomodulation. Furthermore, aging, senescence, and oxidative stress reduce theirex vivoexpansion, which is critical for their clinical applications. Modulation of sirtuin expression and activity may represent a method to reduce oxidative stress in MSCs. These findings have important implications in the clinical utility of MSCs for degenerative and immunological based conditions. Further study of oxidative stress in MSCs is imperative in order to enhance MSCex vivoexpansion andin vivoengraftment, function, and longevity.


2021 ◽  
Author(s):  
Eirini Martinou ◽  
Giulia Falgari ◽  
Angeliki Angelidi ◽  
Izhar Bagwan

Abstract Background: Colorectal cancer (CRC) is worldwide the third leading cause of cancer-related death, and despite therapeutic advances, survival remains low. Emerging evidence shows that Homeobox (HOX) genes are important in carcinogenesis, and their dysregulation has been linked with metastatic potential and poor prognosis. This systematic review aims to present the current evidence on the role of HOX genes as biomarkers in CRC and the impact of their modulation in tumour growth and progression. Methods: MEDLINE, EMBASE, Web of Science and Cochrane databases were searched by following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Eligible studies investigated two research questions: a) the clinicopathological and prognostic significance of HOX gene dysregulation in patients with CRC and b) the functional role of HOX genes in CRC progression. This study was registered in the international prospective register of systematic reviews (PROSPERO), CRD42020190953. Results: Twenty-five studies enrolling 3003 patients with stage I-IV CRC, showed that 26 out of 39 HOX genes were dysregulated in cancerous versus normal colon. Aberrant expression of HOX proteins was significantly related to tumour depth, nodal invasion, distant metastases, advanced stage and poor prognosis. Twenty-two preclinical studies showed that HOX proteins are crucially related to tumour growth and metastatic potential by affecting cell proliferation and altering the expression of epithelial-mesenchymal transition modulators. Conclusions: In conclusion, our findings suggest that HOX proteins play vital roles in CRC progression and significantly affect survival. Further research, though, is required to elucidate their potential role as biomarkers in CRC.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 3689-3689
Author(s):  
Hisayuki Yao ◽  
Yasuo Miura ◽  
Satoshi Yoshioka ◽  
Masaki Iwasa ◽  
Atsushi Sato ◽  
...  

Abstract Clinical studies have shown that exogenously administered culture-expanded human bone marrow mesenchymal stromal/stem cells (BM-MSCs) support hematopoietic cell engraftment and reconstitution after hematopoietic stem cell transplantation (SCT). In addition, these cultured BM-MSCs reveal clinically effective to reduce the side effects of GvHD. Therefore, culture-expanded human BM-MSCs are a promising cell therapy to improve clinical outcome of SCT. We previously reported that culture-expanded human BM-MSCs support the expansion of hematopoietic cells and pharmacological stimulation of BM-MSCs with parathyroid hormone (PTH) further enhances the BM-MSC-mediated expansion of hematopoietic cells. Here, we show that direct interaction with BM-MSCs is required for the hematopoietic expansion mediated by PTH and cadherin-11 (CDH11) is one of responsible molecules. When CD34+ hematopoietic progenitor cells (HPCs) were co-cultured with BM-MSCs in StemSpan Serum Free Expansion Medium (StemCell Technologies) supplemented with 100 ng/mL stem cell factor (SCF), 100 ng/mL Flt-3 ligand, 50 ng/mL thrombopoietin (TPO) and 20 ng/mL interleukin (IL)-3, the number of HPCs was increased. The increase in HPCs number by the co-culture with BM-MSCs was significantly enhanced when these MSCs were pre-stimulated with PTH. This enhancement effect of PTH on HPC expansion was not observed in HPC culture alone in the absence of BM-MSCs, which excluded the direct effects of PTH on HPCs. In the presence of a Transwell (Corning), co-culture of HPCs with BM-MSCs stimulated with PTH (BM-pMSCs) did not bring about the enhancement of HPC expansion. This indicates the requirement of direct interaction between HPCs and BM-MSCs. The possible involvement of adhesion molecule(s) in the enhanced HPC expansion by PTH was supported by the observation that the expression of hematopoiesis-associated soluble factors including SCF, CXCL12, and Angiopoietin1 was not altered in BM-pMSCs compared to untreated BM-MSCs (BM-uMSCs). Next, we performed microarray analysis on BM-pMSCs and found CDH11 was upregulated among various adhesion molecules expressed by BM-MSCs. The upregulated expression of CDH11 was confirmed by immunoblotting analysis in which the level of CDH11 in BM-pMSCs was increased by approximately twice. To examine a functional role of CDH11 on BM-MSCs, siRNA experiments were conducted. When the expression of CDH11 mRNA in BM-MSCs was inhibited by CDH11-specific siRNA by around 85% (Figure 1), the enhancement of HPC expansion was inhibited (Figure 2). This inhibition was not observed when BM-MSCs were treated with scramble siRNA. To further examine a role of CDH11 and PTH on BM-MSCs in hematopoiesis in vivo, bone marrow transplantation experiment was performed. When C57BL/6 mice received suboptimal dose of bone marrow cell transplantation (5 x 104 cells) after lethal irradiation at 10 Gy, the survival rate of mice were about 40%. When PTH was injected subcutaneously to the mice after bone marrow cell transplantation, the survival rate of mice improved to be about 90%. No significant adverse reactions including hypercalcemia were observed after PTH administration. In PTH-treated mice, hematopoietic recover was promoted after lethal irradiation and the following bone marrow transplantation, and the expression of CDH11 in BM-MSC was upregulated compared to the control mice. In conclusion, CDH11 was a functional and indispensable adhesion molecule associated with the enhancement of HPC expansion by BM-MSCs stimulated with PTH. Pharmacological treatment to target the upregulated expression of CDH11 in BM-MSCs could be a novel strategy to obtain hematopoietic expansion in a clinical setting. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document